{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-005802","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.908204+00:00","generated_at":"2026-05-26T23:42:39.859873+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Erasmus MC Safety Committee approves Phase 2 study of Ampligen + Imfinzi for late-stage pancreatic cancer","bullets":["Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.","Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.","CEO Tom Equels and Prof. van Eijck discussed milestone in Virtual Investor segment.","Study is investigator-initiated, single-center at Erasmus MC in the Netherlands."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-005802","json":"https://secwatch.observer/filing/0001493152-25-005802.json","markdown":"https://secwatch.observer/filing/0001493152-25-005802.md","text":"https://secwatch.observer/filing/0001493152-25-005802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315225005802/0001493152-25-005802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315225005802/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:42:39.859873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}